Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05482854 |
|
Recruitment Status :
Not yet recruiting
First Posted : August 1, 2022
Last Update Posted : January 5, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of the trial is to evaluate in ANRS CO6 PRIMO cohort participants if the presence of the MHC B35 (53) Bw4TTC2 genotype favors the control of HIV infection (defined by a viral load (VL) less than 400 cp/mL) after discontinuation of antiretroviral therapy (ART) initiated during primary HIV infection.
The trial will be a pilot "proof of concept", one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months).
It is planned to include between 20 and 50 participants.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections | Other: Analytical Treatment Interruption (ATI) | Not Applicable |
The ANRS 175 RHIVIERA 01 trial will focus on people who were initiated early and have a particular genotypic profile associated with HIV remission.
The study proposes to test an intervention consisting in a ART-treatment interruption (of at least 6 months) in ANRS CO6 PRIMO cohort participants carrying the MHC B35/53Bw4TTC2 genotype and well controlled on cART.
The study aims to enrol 20-30 participants in 30 French clinical sites. Participants will be enrolled after checking eligibility criteria and will interrupt ART immediatly after inclusion.
Control of HIV-Infection, defined by a viral load less than 400 cp/mL, will be evaluated after 24 weeks of interruption.
Study duration will vary by participant, depending on the time of ART interruption and the time to viral rebound. Participants will be followed maximum 48 weeks on ATI. If there is a viral rebound justifying the resumption of ART, participant will be followed 24 weeks maximum after resumption. The maximum duration of the study will be 48+24 = 72 weeks.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 50 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | The trial will be a pilot "proof of concept", one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months). |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | ANRS 175 RHIVIERA-01: Assessment of HIV Remission Upon Combination Antiretroviral Therapy (cART) Interruption in Early Treated Individuals From ANRS CO6 PRIMO Cohort Carrying the Major Histocompatibility Complex (MHC) B35/53Bw4TTC2 Genotype |
| Estimated Study Start Date : | February 2023 |
| Estimated Primary Completion Date : | October 2024 |
| Estimated Study Completion Date : | April 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Patients treated early and carrying the MHC B35/53Bw4TTC2 Genotype
Patients included in the ANRS CO6 PRIMO cohort, treated early and carrying the MHC B35/53Bw4TTC2 Genotype
|
Other: Analytical Treatment Interruption (ATI)
Analytical Interruption of Treatment for 24-48 weeks ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria |
- Proportion of subjects with a Plasma HIV-1 RNA (viral load,VL) below 400 copies/mL at 6 months after Treatment interruption (Week 24). [ Time Frame: Six months after treatment interruption (Week 24). ]Proportion of subjects with a Plasma HIV-1 RNA below 400 copies/mL on subjects included at 6 months after Treatment interruption.
- The acceptation rate of the trial by eligible patients [ Time Frame: At inclusion (Day 0) ]Percentage of patients who accept to participate on patients pré-screened and eligible
- Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following Analytic Treatment Interruption (ATI) [ Time Frame: At 3 months (week 12) and 6 months (week 24) following ATI ]Proportion of patients with a plasma VL < 50 copies/ml at 3 and 6 months following ATI
- Evolution of number of CD4 T cells count during ATI and after ART resumption [ Time Frame: During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks) ]Measurement of CD4 T cells count at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
- Evolution of CD4 to CD8 ratio during ATI and after ART resumption [ Time Frame: During all ATI period (from Day 0 to Day 0 ART resumption - maximum 48 weeks) and during ART resumption period (maximum 24 Weeks) ]Measurement of CD4 to CD8 at Screening, Day 0, Week 2, Week 4, Week 6, Week 8, Week 12, Week 16, Week 20, Week 24, Week 36, Week 48, Day 0 ART resumption, Week 4 resumption, Week 12 resumption, Week 24 resumption
- Evolution of total and integrated HIV DNA and cell-associated HIV RNA transcripts [ Time Frame: During ATI period (At Day 0, Week 4, Week 12, Week 24) and during ART resumption period (at Day 0 Resumption, and Week 24 ART Resumption) ]Quantification of total HIV-DNA and integrated HIV-DNA by ultrasensitive techniques (ultrasensitive real-time PCR and Alu PCR) Quantification of intracellular HIV-RNA transcripts by ultrasensitive technique (ultrasensitive qPCR gag).
- Evolution of HIV markers in sperm (on 25 participants) [ Time Frame: During ATI period (At Day 0, Week 4, Week 12, Week 24) and at Day 0 ART resumption ]Quantification of HIV DNA on semen cells (ultrasensitive technique) and quantification of HIV RNA on seminal fluid (ultrasensitive technique)
- Evolution of the levels of inflammation markers during ATI [ Time Frame: During ATI period (up to week 24 ATI) and at Day 0 ART resumption ]Physiological parameters levels will be studied (Luminex and Simoa technology): IFNα, TGFβ, IL-7, IL-12, IL-15, IL-18, IP-10, DPPIV, ARNr 16S, I-FABP, citrulline, sCD14, sCD163
- Proportion of patients who resumed treatment during the first 6 months of ATI, according to the reasons for resuming [ Time Frame: At week 24 ]Percentage of resumption, according to the reasons listed in the protocol, before the evaluation of the primary outcome
- Pharmacological dosages of antiretrovirals performed during the ATI from frozen samples [ Time Frame: At Week 2 and Week 24 of ATI ]Pharmacological dosages of antiretrovirals performed during the ATI at Week 2 and Week 24 of ATI
- Proportion of patients reporting at each visit to use condoms [ Time Frame: From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year). ]Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
- Proportion of patients reporting at each visit to have proposed PrEP at their partners [ Time Frame: From date of inclusion to the last follow-up visit, up to 72 weeks (average of 1 year). ]Document the emphasis being placed on the impact of access to information on prevention behaviors and the quality of sexual life.
- Proportion of patients satisfied with their participation at the end of the trial [ Time Frame: Questionnaire at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate) ]
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
- Evolution of the level of the quality of life between inclusion and the end of the trial [ Time Frame: Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate) ]Through statistical analyses of some self-administered questionnaires items ( SF12.v2 scale for quality of life). The 12-item Short-Form Health Survey is a widely used, generic patient-reported measure of health status that provides summary scores of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
- Evolution of the global satisfaction with sexual life between inclusion and the end of the trial [ Time Frame: Questionnaire at Day 0, at Week 24 (or resumption of ART) and at the end of the study (Week 48 ou Week 24 resumption). Questionnaire at screening (in case of refusal to participate) ]
Through statistical analyses of some self-administered questionnaires items (Likert).
On a Likert scale, a person selects one option among several that reflects how much they agree with a statement. The scale generally consists of five or seven balanced responses that people can choose from.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 18 years at the time of consent
- Enrolled and currently followed in the ANRS CO6 PRIMO Cohort
- With the MHC genotype: at least one HLA B35 or B53 allele AND one HLA-A or B allele carrying the Bw4 epitope AND homozygous -21T residue in the HLA-B alleles AND heterozygous or homozygous for C2 epitope-carrying HLA-C alleles
- Treated with cART within 3 months following inclusion in ANRS CO6 Primo Cohort during at least 18 months and cART not modified in the last 3 months
- Controlled on cART: > 90% of VL below the threshold after initial virological response
- All VL below the threshold during the previous 12 months
- Most recent CD4 measurement on cART above 500 cells/mm3
- Written and informed consent signed by the person and the investigator (no later than the day of pre-inclusion and prior to any examination realized in the frame of the study (article L1122-1-1 of the Public Health Code)
- Person affiliated or beneficiary of a social security scheme (article L1121-11 of the Public Health Code) (State Medical Aid or AME is not a social security scheme)
- Patient agreeing to participate in the trial according to the defined procedures.
Exclusion Criteria:
- One VL above 1000 cp/mL on or off antitretrovirals after the initial viral control on antiretrovirals was achieved.
- Patient in whom condom sex use or PrEP use by the partner will be difficult or impossible.
- Woman with a pregnancy project and pregnant woman.
- Patient under guardianship or curatorship.
- History of a clinical AIDS event or cancer.
- Active HCV or HBV infection.
- Any symptoms or laboratory values suggesting a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions, related to HIV or not, which contraindicates the interruption of ARVs.
- Recent SARS-CoV-2 infection and / or associated with a drop in CD4 and / or associated with a resumption of CV in the last 6 months. In this situation, wait until the CD4 has returned to a rate > 500/mm3 and a CV < 50 copies / mL consolidated for > 6 months.
- Affection, disability, resulting from a SARS-CoV-2 infection, regardless of the duration of the SARS-CoV-2 infection.
- Patient participating in another research evaluating other treatments with an exclusion period ongoing at the screening visit.
- Planned absence which could prevent optimal trial participation (vacation abroad, moving, imminent job change ...).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05482854
| Contact: Vincent MEIFFREDY | 00 33 1 45 59 52 06 | vincent.meiffredy@inserm.fr | |
| Contact: Nicolas LETURQUE | 00 33 1 45 59 51 93 | nicolas.leturque@inserm.fr |
Show 30 study locations
| Principal Investigator: | Cécile GOUJARD | Hôpital Bicêtre, Service de médecine interne et d'immunologie clinique |
| Responsible Party: | ANRS, Emerging Infectious Diseases |
| ClinicalTrials.gov Identifier: | NCT05482854 |
| Other Study ID Numbers: |
ANRS 175 RHIVIERA-01 |
| First Posted: | August 1, 2022 Key Record Dates |
| Last Update Posted: | January 5, 2023 |
| Last Verified: | July 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
treatment interruption HIV remission Post-treatment control HLA-B35 Early treatment |
|
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections |
Retroviridae Infections RNA Virus Infections Virus Diseases Genital Diseases Urogenital Diseases Immunologic Deficiency Syndromes Immune System Diseases |